BR112014029219A2 - - Google Patents

Info

Publication number
BR112014029219A2
BR112014029219A2 BR112014029219A BR112014029219A BR112014029219A2 BR 112014029219 A2 BR112014029219 A2 BR 112014029219A2 BR 112014029219 A BR112014029219 A BR 112014029219A BR 112014029219 A BR112014029219 A BR 112014029219A BR 112014029219 A2 BR112014029219 A2 BR 112014029219A2
Authority
BR
Brazil
Application number
BR112014029219A
Other languages
Portuguese (pt)
Other versions
BR112014029219B1 (pt
BR112014029219A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014029219(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR112014029219A2 publication Critical patent/BR112014029219A2/pt
Publication of BR112014029219A8 publication Critical patent/BR112014029219A8/pt
Publication of BR112014029219B1 publication Critical patent/BR112014029219B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014029219-1A 2012-05-23 2013-05-23 Anticorpo ou fragmento de ligação ao antígeno, uso dos mesmos e composição farmacêutica BR112014029219B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261650883P 2012-05-23 2012-05-23
US61/650.883 2012-05-23
US201261720102P 2012-10-30 2012-10-30
US61/720.102 2012-10-30
PCT/IB2012/056424 WO2013175276A1 (en) 2012-05-23 2012-11-14 Il-6 binding molecules
IBPCT/IB2012/056424 2012-11-14
PCT/IB2013/054271 WO2013175427A1 (en) 2012-05-23 2013-05-23 Il-6 binding molecules

Publications (3)

Publication Number Publication Date
BR112014029219A2 true BR112014029219A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-08-15
BR112014029219A8 BR112014029219A8 (pt) 2019-05-14
BR112014029219B1 BR112014029219B1 (pt) 2022-04-19

Family

ID=47559582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029219-1A BR112014029219B1 (pt) 2012-05-23 2013-05-23 Anticorpo ou fragmento de ligação ao antígeno, uso dos mesmos e composição farmacêutica

Country Status (17)

Country Link
US (4) US10183995B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2852616A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6410712B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150063311A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103601806B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013264779B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014029219B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2871148C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014003167A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7240362A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14029713A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL235134B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX360163B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ701370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20150335A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2676078C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO2013175276A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113117074B (zh) 2015-07-31 2025-09-12 米迪缪尼有限公司 用于治疗海帕西啶介导的病症的方法
CN105194655A (zh) * 2015-10-21 2015-12-30 胶州市人民中医医院 一种新生儿细菌感染性脑炎的治疗方法
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
SG11201906852XA (en) 2017-02-01 2019-08-27 Univ Yale Treatment of diuretic resistance
US20190241650A1 (en) 2018-01-05 2019-08-08 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
CN111153998B (zh) * 2020-01-16 2022-06-24 佛山汉腾生物科技有限公司 抗ctla-4纳米抗体及其应用
EP4138888A1 (en) * 2020-04-23 2023-03-01 Eli Lilly and Company Subcutaneous absorption and bioavailability of antibodies
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
WO2023229891A1 (en) * 2022-05-25 2023-11-30 Ayuvis Research, Inc. Novel immunodulating small molecules
CN119331091B (zh) * 2024-11-06 2025-05-13 重庆探生科技有限公司 一种抗人白介素6的单克隆抗体及其应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JP2001506967A (ja) 1996-08-02 2001-05-29 ブリストル―マイヤーズ・スクイブ・カンパニー 治療およびインビボ診断における免疫グロブリンの使用の結果としての免疫グロブリン誘発毒性の抑制方法
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
EP2149604A1 (en) 2000-09-08 2010-02-03 Universität Zürich Collections of repeat proteins comprising repeat modules
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7291721B2 (en) * 2001-11-14 2007-11-06 Centocor, Inc. Anti-IL-6 antibodies, compositions, methods and uses
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2003279719B8 (en) 2002-09-27 2009-01-08 Xencor Inc. Optimized Fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
KR101149242B1 (ko) 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Ｆｃ 영역 변이체
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1773872B1 (en) 2004-05-21 2017-03-15 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
AR057227A1 (es) * 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
WO2007066082A1 (en) * 2005-12-09 2007-06-14 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
WO2007104529A2 (en) * 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JP2009545319A (ja) * 2006-08-03 2009-12-24 バクシネックス，インコーポレーテッド 抗ｉｌ−６モノクローナル抗体およびその使用
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
KR101829776B1 (ko) 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
JP5789192B2 (ja) * 2008-11-13 2015-10-07 フェムタ ファーマシューティカルズ インコーポレイテッドＦｅｍｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒト化抗ｉｌ−６抗体
JP2012516158A (ja) 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用
JP2013507124A (ja) 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｉｌ−２３ｒを結合するポリペプチド

Also Published As

Publication number Publication date
CN103601806B (zh) 2019-01-18
AU2013264779A1 (en) 2014-10-30
WO2013175276A1 (en) 2013-11-28
ECSP14029713A (es) 2015-09-30
US20220073604A1 (en) 2022-03-10
EP2852616A1 (en) 2015-04-01
AU2013264779B2 (en) 2018-03-22
CA2871148A1 (en) 2013-11-28
US11827701B2 (en) 2023-11-28
MX360163B (es) 2018-10-09
MX2014014218A (es) 2015-11-23
CN103601806A (zh) 2014-02-26
NZ701370A (en) 2016-11-25
JP6410712B2 (ja) 2018-10-24
WO2013175427A1 (en) 2013-11-28
BR112014029219B1 (pt) 2022-04-19
US20190233509A1 (en) 2019-08-01
PE20150335A1 (es) 2015-03-20
IL235134A0 (en) 2014-12-31
US10183995B2 (en) 2019-01-22
US20150140011A1 (en) 2015-05-21
CA2871148C (en) 2020-07-14
RU2014152006A (ru) 2016-07-20
BR112014029219A8 (pt) 2019-05-14
KR20150063311A (ko) 2015-06-09
US11117959B2 (en) 2021-09-14
CL2014003167A1 (es) 2015-06-12
RU2676078C2 (ru) 2018-12-26
CO7240362A2 (es) 2015-04-17
IL235134B (en) 2019-12-31
US20240158492A1 (en) 2024-05-16
JP2015518857A (ja) 2015-07-06

Similar Documents

Publication Publication Date Title
BR112014017635A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017614A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017625A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017659A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017592A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017646A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014025384A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR092201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112013027865A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017634A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017644A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017588A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017618A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017647A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014013184A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017623A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017630A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017652A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017631A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017627A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017641A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017621A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017622A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014029219A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014020276A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25D Requested change of name of applicant approved

Owner name: ARGENX N.V. (NL)

B25D Requested change of name of applicant approved

Owner name: ARGENX S.E. (NL)

B25A Requested transfer of rights approved

Owner name: ARGENX BVBA (BE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2013, OBSERVADAS AS CONDICOES LEGAIS.